Cullinan Oncology Ownership | Who Owns Cullinan Oncology?


OverviewForecastFinancialsChart

Cullinan Oncology Ownership Summary


Cullinan Oncology is owned by 111.43% institutional investors, 4.50% insiders. Bioimpact capital is the largest institutional shareholder, holding 17.78% of CGEM shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.58% of its assets in Cullinan Oncology shares.

CGEM Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCullinan Oncology111.43%4.50%-15.93%
SectorHealthcare Stocks 47.06%8.01%44.93%
IndustryBiotech Stocks 44.97%7.82%47.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bioimpact capital7.65M17.78%$133.39M
Bvf inc/il5.75M13.37%$100.29M
Blackrock3.55M8.25%$61.92M
Deerfield management company, l.p. (series c)3.28M7.63%$57.21M
Vanguard group2.87M6.68%$50.08M
Franklin resources2.44M5.68%$42.63M
Adage capital partners gp2.23M5.19%$38.94M
Blue owl capital lp2.05M4.76%$35.74M
State street1.94M4.51%$33.85M
Alliancebernstein1.73M4.02%$30.15M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Bioimpact capital7.65M20.73%$133.39M
Blue owl capital lp2.05M9.94%$35.74M
Foresite capital management v657.90K7.33%$11.47M
Nextech invest1.22M3.58%$21.30M
Bvf inc/il5.75M2.81%$100.29M
Twin focus capital partners595.49K1.66%$10.39M
Tang capital management921.14K1.64%$16.06M
Vr adviser1.38M1.53%$24.07M
Avidity partners management lp1.56M1.16%$27.20M
Paradigm biocapital advisors lp1.54M1.03%$26.91M

Top Buyers

HolderShares% AssetsChange
Bvf inc/il5.75M2.81%2.55M
Deerfield management company, l.p. (series c)3.28M0.95%2.14M
Alliancebernstein1.73M0.01%1.70M
Avidity partners management lp1.56M1.16%1.56M
Vr adviser1.38M1.53%1.38M

Top Sellers

HolderShares% AssetsChange
Cormorant asset management, lp---1.13M
Braidwell lp176.17K0.10%-1.06M
Blue owl capital lp2.05M9.94%-875.67K
Perceptive advisors---749.92K
Logos global management lp---700.00K

New Positions

HolderShares% AssetsChangeValue
Avidity partners management lp1.56M1.16%1.56M$27.20M
Vr adviser1.38M1.53%1.38M$24.07M
Holocene advisors, lp1.32M0.10%1.32M$22.95M
Artal group1.06M0.47%1.06M$18.45M
Rtw investments, lp1.05M0.28%1.05M$18.36M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-5.00
Advisor group-50.00
Simplex trading-119.00
Pacer advisors-595.00
Newedge advisors-723.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20241423.65%65,005,6963.31%1110.85%85-14.14%2812.00%
Jun 30, 202413618.26%62,925,23359.82%1461.73%9860.66%25-30.56%
Mar 31, 20241151.77%39,373,0466.88%921.24%61-11.59%3656.52%
Dec 31, 20231136.60%36,838,443-3.03%860.95%6950.00%23-25.81%
Sep 30, 2023106-0.93%37,989,7603.06%951.16%46-11.54%31-18.42%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.50M2.58%2.18K
iShares Russell 2000 ETF1.34M2.30%-3.01K
SPDR® S&P Biotech ETF1.26M2.18%13.99K
Franklin Biotechnology Discv A(acc)USD842.14K1.45%-37.10K
AB Small Cap Growth A839.90K1.45%19.55K
Franklin US Small Cap Growth Equity791.57K1.37%-8.13K
Franklin Small Cap Growth Adv791.57K1.37%-
Vanguard Institutional Extnd Mkt Idx Tr763.53K1.32%11.02K
Franklin Biotechnology Discovery A483.95K0.83%-21.00K
iShares Russell 2000 Growth ETF407.14K0.70%-

Recent Insider Transactions


DateNameRoleActivityValue
Nov 05, 2024Michaelson Jennifer Chief Scientific OfficerSell$125.12K
Sep 05, 2024Michaelson Jennifer Chief Scientific OfficerSell$144.72K
Jul 05, 2024Michaelson Jennifer Chief Scientific OfficerSell$130.64K
May 06, 2024Michaelson Jennifer Chief Scientific OfficerSell$578.71K
May 07, 2024Michaelson Jennifer Chief Scientific OfficerSell$168.52K

Insider Transactions Trends


DateBuySell
2024 Q4-1
2024 Q3-2
2024 Q2-3
2024 Q1-5
2023 Q4-11

CGEM Ownership FAQ


Who Owns Cullinan Oncology?

Cullinan Oncology shareholders are primarily institutional investors at 111.43%, followed by 4.50% insiders and -15.93% retail investors. The average institutional ownership in Cullinan Oncology's industry, Biotech Stocks , is 44.97%, which Cullinan Oncology exceeds.

Who owns the most shares of Cullinan Oncology?

Cullinan Oncology’s largest shareholders are Bioimpact capital (7.65M shares, 17.78%), Bvf inc/il (5.75M shares, 13.37%), and Blackrock (3.55M shares, 8.25%). Together, they hold 39.41% of Cullinan Oncology’s total shares outstanding.

Does Blackrock own Cullinan Oncology?

Yes, BlackRock owns 8.25% of Cullinan Oncology, totaling 3.55M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 61.92M$. In the last quarter, BlackRock increased its holdings by 1.12M shares, a 46.16% change.

Who is Cullinan Oncology’s biggest shareholder by percentage of total assets invested?

Bioimpact capital is Cullinan Oncology’s biggest shareholder by percentage of total assets invested, with 20.73% of its assets in 7.65M Cullinan Oncology shares, valued at 133.39M$.

Who is the top mutual fund holder of Cullinan Oncology shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Cullinan Oncology shares, with 2.58% of its total shares outstanding invested in 1.5M Cullinan Oncology shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools